Synthetic Strategy and Evaluation of the Benzyloxy Benzylamide Derivatives as Thymic Stromal Lymphopoietin Modulators for the Treatment of Atopic Dermatitis.

Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by immune dysregulation, in which thymic stromal lymphopoietin (TSLP) plays a critical role by triggering type 2 inflammation and exacerbating disease progression. In this study, a screening of our in-house library for inhibition of CCL17 mRNA expression led to identification of hit compound 6a. Based on this scaffold, benzyloxy benzylamide derivatives were systematically designed and synthesized, followed by the evaluation of their anti-inflammatory potential. Among them, compound 14o exhibited the most potent inhibition of CCL17 and IL-1B mRNA expression in HaCaT keratinocytes, along with favorable drug-like properties. 14o interfered with TSLP receptor dimerization and suppressed the TSLP-induced signal transducer and activator of transcription 5 phosphorylation. Furthermore, 14o significantly attenuated TSLP-induced calcium influx and effectively alleviated pruritus and AD-like symptoms in a house dust mite (HDM)-induced AD mouse model. Collectively, these findings highlight 14o as a promising topical therapeutic candidate targeting TSLP signaling for the treatment of AD.

• Publication year

  2025

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2025-12-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.5c02461PMID 41467342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opportunities of Topical Drug Products in a Changing Dermatological Landscape.

  2024cited by this paper
• Anti-Allergic and Anti-Inflammatory Signaling Mechanisms of Natural Compounds/Extracts in In Vitro System of RBL-2H3 Cell: A Systematic Review

  2024cited by this paper
• Disrupting TSLP–TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases

  2024cited by this paper
• Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis

  2023cited by this paper
• Epidermal keratinocyte-specific STAT3 deficiency aggravated atopic dermatitis-like skin inflammation in mice through TSLP upregulation

  2023cited by this paper
• Serum thymic stromal lymphopoietin (TSLP) levels in atopic dermatitis patients: a systematic review and meta-analysis

  2023cited by this paper
• Atopic dermatitis in 2023 and beyond.

  2023cited by this paper
• The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target

  2023cited by this paper
• Inhibition of thymic stromal lymphopoietin production by FK3453.

  2022cited by this paper
• Context-dependent function of TSLP and IL-1β in skin allergic sensitization and atopic march

  2022cited by this paper
• New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature

  2022cited by this paper
• Peripheral itch sensitization in atopic dermatitis.

  2022cited by this paper
• Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies.

  2022cited by this paper
• Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases

  2021cited by this paper
• Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

  2021cited by this paper
• Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies.

  2021cited by this paper
• Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis

  2020cited by this paper
• Atopic dermatitis

  2020cited by this paper
• Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation

  2020cited by this paper
• Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

  2019cited by this paper
• Structure-Activity Relationships of Baicalein and its Analogs as Novel TSLP Inhibitors

  2019cited by this paper
• CCL2/CCR2 signaling elicits itch- and pain-like behavior in a murine model of allergic contact dermatitis.

  2019cited by this paper
• Optimization of Cytokine Milieu to Reproduce Atopic Dermatitis-related Gene Expression in HaCaT Keratinocyte Cell Line

  2018cited by this paper
• TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state

  2018cited by this paper
• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

  2016cited by this paper
• Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

  2016cited by this paper
• Biomarkers for atopic dermatitis: a systematic review and meta-analysis

  2015cited by this paper
• TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling

  2014cited by this paper
• Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis

  2013cited by this paper
• Role of interleukin 1 in atopic dermatitis.

  2013cited by this paper
• The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch.

  2013cited by this paper
• Atopic dermatitis: from new pathogenic insights toward a barrier-restoring and anti-inflammatory therapy

  2011cited by this paper
• Th2 Cytokines and Atopic Dermatitis.

  2011cited by this paper
• Sulforaphane suppresses TARC/CCL17 and MDC/CCL22 expression through heme oxygenase-1 and NF-κB in human keratinocytes

  2010cited by this paper
• Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function

  2010cited by this paper
• Dibutyl Phthalate-Induced Thymic Stromal Lymphopoietin Is Required for Th2 Contact Hypersensitivity Responses

  2010cited by this paper
• Thymic stromal lymphopoietin

  2010cited by this paper
• Atopic dermatitis: a review of topical treatment options

  2010cited by this paper
• Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7–induced signaling

  2010cited by this paper
• TSLP acts on infiltrating effector T cells to drive allergic skin inflammation

  2008cited by this paper
• Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation.

  2007cited by this paper
• A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/Nga mice.

  2007cited by this paper
• Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFκB

  2007cited by this paper
• TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation.

  2007cited by this paper
• Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB.

  2007cited by this paper
• TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand

  2005cited by this paper
• Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin

  2005cited by this paper
• TGF-beta/Smad signaling inhibits IFN-gamma and TNF-alpha-induced TARC (CCL17) production in HaCaT cells.

  2003cited by this paper
• Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP

  2002cited by this paper
• Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

  2002cited by this paper
• Human Thymic Stromal Lymphopoietin Preferentially Stimulates Myeloid Cells1

  2001cited by this paper
• Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.

  1994cited by this paper

• No citing papers are available for this paper.